Indian scientists uncover IL-35 protein for breakthroughs in type 1 and autoimmune diabetes treatment

In a promising development for diabetes treatment, researchers at the Institute of Advanced Study in Science and Technology (IASST) in India have identified the IL-35 protein, which could pave the way for innovative therapies for type 1 and autoimmune diabetes by reducing harmful immune responses. This is reported by IANS, a partner of TV BRICS.

The source claims that IL-35 helps protect pancreatic cells by lowering specific immune cells that produce inflammatory agents, thus reducing pancreatic cell infiltration, a major factor in type 1 diabetes mellitus.

The IL-35 protein, composed of IL-12 alpha and IL-27 beta chains, plays a protective role in the immune system by regulating macrophage activation, T-cell proteins, and regulatory B cells. This regulation helps prevent immune cells from targeting pancreatic beta cells, thereby reducing inflammation and supporting overall immune health.

Through network pharmacological analysis, the team identified five disease-interacting genes associated with immune-inflammatory and autoimmune disorders, reinforcing the potential of IL-35 in diabetes treatment.

The IASST scientists are now advocating for additional studies to better understand IL-35’s mechanisms and support the progression of IL-35-based therapies into clinical trials, highlighting the protein's potential to revolutionise diabetes treatment.

Photo: iStock